| Literature DB >> 30019024 |
Rosa Falcone1, Valeria Ramundo1, Livia Lamartina1, Valeria Ascoli2, Daniela Bosco2, Cira Di Gioia2, Teresa Montesano1, Marco Biffoni3, Marco Bononi4, Laura Giacomelli3, Antonio Minni5, Maria Segni6, Marianna Maranghi1, Vito Cantisani2, Cosimo Durante1, Giorgio Grani1.
Abstract
Incidental sonographic discovery of thyroid nodules is an increasingly common event. The vast majority is benign, and those that are malignant, are generally associated with an indolent course and low mortality. Sonographic scoring systems have been developed to help clinicians identify nodules that warrant prompt fine-needle aspiration cytology (FNAC), but they are based largely on experience with papillary thyroid cancers. We analyzed the performance of four scoring systems widely used for this purpose (American Thyroid Association Guidelines, American Association of Clinical Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi Guidelines, European Thyroid Imaging Reporting and Data System, and Korean Thyroid Imaging Reporting and Data System) in patients whose nodules proved to be metastases from other solid cancers. Such nodules reportedly account for 0.2% to 3% of all thyroid malignancies. Each scoring system was used to assess retrospectively the malignancy risk and indications for FNAC of five patients' thyroid nodules that were ultimately diagnosed as metastases (from renal cell carcinoma, breast cancer, and lung cancer in two cases and esophageal cancer). The primaries identified in these cases are those most commonly reported to metastasize to the thyroid. In two cases, the thyroid metastases were the first sign of undetected neoplastic disease. Although sonography alone cannot distinguish thyroid metastases from primary thyroid malignancies, all four scoring systems classified the metastatic nodules as suspicious enough to require FNAC. The five cases accounted for 0.2% of those cytologically examined in our center. In most cases, cytology provided useful guidance for the subsequent management of these lesions, which differs from that of primary thyroid cancers and requires multidisciplinary input.Entities:
Keywords: TIRADS; cytology; diagnosis; fine-needle aspiration; metastasis; thyroid nodule
Year: 2018 PMID: 30019024 PMCID: PMC6041777 DOI: 10.1210/js.2018-00124
Source DB: PubMed Journal: J Endocr Soc ISSN: 2472-1972
Features of the Metastatic Thyroid Nodules and Their Sonographically Estimated Risks of Malignancy
| Case/Source of the Metastasis | Sonographic Features | Estimated Risk of Malignancy |
|---|---|---|
| Patient 1—Renal cell carcinoma [ | Solid, inhomogeneous (central hypoechogenicity), smooth margins | AACE: intermediate ATA: intermediate |
| Dimensions: 9.5 × 8.7 × 17.5 mm | EU-TIRADS: 4 K-TIRADS: 4 | |
| Patient 2—Lung adenocarcinoma [ | Solid, hypoechoic, irregular margins Dimensions: 13.3 × 17.6 × 20.4 mm | AACE: high ATA: high EU-TIRADS: 5 K-TIRADS: 5 |
| Patient 3—Breast cancer [ | Solid, hypoechoic, irregular margins Dimensions: 20.3 × 16.9 × 25.9 mm One suspicious lymph node (ipsilateral) | AACE: high ATA: high EU-TIRADS: 5 K-TIRADS: 5 |
| Patient 4—Esophageal cancer [ | Solid, markedly hypoechoic, irregular margins Dimensions: 20.7 × 20.8 × 32.3 mm Suspicious lymph nodes (bilateral) | AACE: high ATA: high EU-TIRADS: 5 K-TIRADS: 5 |
| Patient 5—Lung cancer [ | Solid, hypoechoic with focal marked hypoechogenicity, irregular margins Dimensions: 23 × 22 mm Suspicious lymph nodes (bilateral) | AACE: high ATA: high EU-TIRADS: 5 K-TIRADS: 5 |
TIRADS 4 and 5 indicate nodules with intermediate and high suspicion of malignancy, respectively.
Abbreviations: AACE, American Association of Clinical Endocrinologists; ATA, American Thyroid Association; EU-TIRADS, European Thyroid Imaging Reporting and Data System; K-TIRADS, Korean Thyroid Imaging Reporting and Data System.
Figure 1.Ultrasonographic images of the metastatic lesions (A) renal cell carcinoma metastasis to the thyroid; (B) thyroid metastasis from lung adenocarcinoma; (C) thyroid metastasis and (D) level 2 cervical lymph node metastasis from breast cancer; (E) thyroid metastasis from esophageal cancer; and (F) thyroid metastasis from lung cancer. Detailed descriptions and US classifications are provided in Table 1.